CL2025003637A1 - Anticuerpos anti-tgf-beta 1 latente y métodos de uso. - Google Patents

Anticuerpos anti-tgf-beta 1 latente y métodos de uso.

Info

Publication number
CL2025003637A1
CL2025003637A1 CL2025003637A CL2025003637A CL2025003637A1 CL 2025003637 A1 CL2025003637 A1 CL 2025003637A1 CL 2025003637 A CL2025003637 A CL 2025003637A CL 2025003637 A CL2025003637 A CL 2025003637A CL 2025003637 A1 CL2025003637 A1 CL 2025003637A1
Authority
CL
Chile
Application number
CL2025003637A
Inventor
Savory Nasa
Ikawa Yuri
KANAMORI Masakazu
Mori Keita
SHIRAI Kazuhide
TAKIZAWA Shuuki
Original Assignee
Chugai Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kk filed Critical Chugai Seiyaku Kk
Publication of CL2025003637A1 publication Critical patent/CL2025003637A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un objetivo de la invención es proporcionar anticuerpos anti-TGF-beta 1 latente y métodos para utilizar dichos anticuerpos. La presente invención proporciona anticuerpos anti-TGF-beta 1 latente que inhiben una activación mediada por proteasa de TGF-beta 1 latente sin inhibir la activación mediada por integrina de TGF-beta 1 latente o con inhibición parcial de la activación mediada por integrina de TGF-beta 1 latente, o que inhiben una activación mediada por proteasa de TGF-beta 1 latente, pero tienen menos impacto en la inhibición de la activación mediada por integrina de TGF-beta 1 latente. La invención también proporciona anticuerpos anti-TGF-beta 1 latente optimizados en los que se mejora la propiedad de unión dependiente del pH. Los anticuerpos anti-TGF-beta 1 latente se pueden utilizar para tratar la fibrosis o el cáncer. Por ejemplo, la fibrosis renal, la fibrosis hepática y la fibrosis pulmonar pueden tratarse utilizando los anticuerpos anti-TGF-beta 1 latente.
CL2025003637A 2023-02-10 2025-11-20 Anticuerpos anti-tgf-beta 1 latente y métodos de uso. CL2025003637A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2023019304 2023-02-10

Publications (1)

Publication Number Publication Date
CL2025003637A1 true CL2025003637A1 (es) 2026-03-06

Family

ID=92263024

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2025002306A CL2025002306A1 (es) 2023-02-10 2025-08-04 Anticuerpos anti-tgf-beta 1 latente y métodos de uso
CL2025003637A CL2025003637A1 (es) 2023-02-10 2025-11-20 Anticuerpos anti-tgf-beta 1 latente y métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2025002306A CL2025002306A1 (es) 2023-02-10 2025-08-04 Anticuerpos anti-tgf-beta 1 latente y métodos de uso

Country Status (15)

Country Link
US (1) US20240376190A1 (es)
EP (1) EP4662245A1 (es)
JP (1) JP2024119756A (es)
KR (1) KR20250148627A (es)
CN (1) CN120835902A (es)
AR (1) AR131841A1 (es)
AU (1) AU2024217529A1 (es)
CL (2) CL2025002306A1 (es)
CO (1) CO2025011604A2 (es)
CR (1) CR20250373A (es)
IL (1) IL322242A (es)
MX (1) MX2025009136A (es)
PE (1) PE20252310A1 (es)
TW (1) TW202448961A (es)
WO (1) WO2024166996A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2018043734A1 (en) 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
US20210115122A1 (en) * 2018-02-23 2021-04-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso

Also Published As

Publication number Publication date
KR20250148627A (ko) 2025-10-14
MX2025009136A (es) 2025-09-02
PE20252310A1 (es) 2025-09-22
US20240376190A1 (en) 2024-11-14
IL322242A (en) 2025-09-01
AR131841A1 (es) 2025-05-07
CL2025002306A1 (es) 2025-11-14
CN120835902A (zh) 2025-10-24
CO2025011604A2 (es) 2025-09-08
WO2024166996A1 (en) 2024-08-15
JP2024119756A (ja) 2024-09-03
TW202448961A (zh) 2024-12-16
EP4662245A1 (en) 2025-12-17
AU2024217529A1 (en) 2025-08-07
CR20250373A (es) 2025-10-03

Similar Documents

Publication Publication Date Title
CL2025003637A1 (es) Anticuerpos anti-tgf-beta 1 latente y métodos de uso.
BR102022025291A2 (es)
CL2026000520A1 (es) Una estructura de jaula flotante para peces con faldón contra piojos
BR102023014872A2 (es)
BR102023012440A2 (es)
BR102023010976A2 (es)
BR102023008688A2 (es)
BR102023007252A2 (es)
BR102023005164A2 (es)
BR102023001877A2 (es)
BR102023000289A2 (es)
BR102022026909A2 (es)
BR102022023461A2 (es)
BR202022009269U2 (es)
BR202022005961U2 (es)
BR202022001779U2 (es)
BR202022000931U2 (es)
BY13145U (es)
BY13137U (es)
CN307047164S (es)
CN307047105S (es)
CN307046551S (es)
CN307046214S (es)
CN307049200S (es)
CN307045920S (es)